Compare ANY & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANY | AKTX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 11.5M |
| IPO Year | 2020 | 2014 |
| Metric | ANY | AKTX |
|---|---|---|
| Price | $1.83 | $0.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $30.00 | $2.53 |
| AVG Volume (30 Days) | ★ 639.6K | 186.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,608,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.57 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $0.22 |
| 52 Week High | $1.94 | $1.72 |
| Indicator | ANY | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 71.25 | 52.60 |
| Support Level | $0.39 | $0.22 |
| Resistance Level | $1.94 | $0.27 |
| Average True Range (ATR) | 0.20 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 86.69 | 59.00 |
Sphere 3D Corp provides solutions for stand-alone storage and technologies that converge the traditional silos of compute, storage, and network into integrated hyper-converged or converged solution. Its Disk systems include HVE Converged and Hyper-converged Infrastructure. It generates the majority of its revenue from the services it offers. All of its revenue comes from the Americas. The Company has two operating segments: Bitcoin Mining and Service and Product. The Bitcoin Mining segment generates revenue from the digital currency, it earns through its bitcoin mining activities. The Service and Product segment generates revenue from long-term customer contracts for service contracts and extended service contract and the sale of products related to the Company's data storage product line.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.